Overview

A Study to Assess the Relative Bioavailability of Two Formulations of Risankizumab Following Subcutaneous Administration With Prefilled Syringes in Healthy Adult Participants

Status:
COMPLETED

Trial end date:
2025-04-16

Target enrollment:

Participant gender:

Summary

This study will assess the pharmacokinetics, relative bioavailability and tolerability of two formulations of risankizumab following subcutaneous (SC) administration in healthy adult participants.

Phase:

PHASE1

Details

Lead Sponsor:

AbbVie

Treatments:

risankizumab